GLP1R and type 2 diabetes mellitus: In meta-analysis of randomized clinical trials, GLP-1r agonists were reported with a neutral or slightly beneficial effects on reducing the incidence of bone fracture (21), although more recent data suggest that liraglutide and lixisenatide contribute to reduce fracture in individuals affected by type 2 diabetes mellitus (22).